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Abstract: Antiplatelet therapy reduces the
risk of subsequent ischemic events in patients
suffering from acute myocardial infarction
(AMI). In this respect, the multi-agent therapy
to be used along with aspirin remains to be
determined. In this study, ticlopidine was tried
in AMI for its potential additive effects over
aspirin. Ninety patients with similar clinical
characteristics were involved and were
followed up for 3 and 6 months. All patients
were assigned to receive ticlopidine plus
aspirin or aspirin alone. Major cardiac events
such as death and reinfarction were primary
end-points whereas the need for
revascularization was the secondary end-point
at 3 and 6 months. Although no variable was
significantly different, it was noteworthy that
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the ticlopidine group showed less need for
revascularization (mainly coronary bypass
surgery at 3 and 6 months (15.9% vs.
30.4%, 20.5% vs. 30.4%) and reinfarction
rates (4.5% vs. 10.9% and 6.8% vs. 13%).
This study was one of the few to evaluate the
effects of adjunctive ticlopidine treatment in
AMI. Despite the lack of significant superiority
over aspirin alone, the additional effects of
ticlopidine could be a reduction in reinfarction
rates and the need for bypass surgery at 3and 6-months if more patients were involved.
Nevertheless, comprehensive, large-scale
studies are essential to disclose the net effect.
Key Words: Acute myocardial infarction,
aspirin, ticlopidine

Introduction

Materials and Methods

The pathophysiology of acute coronary syndromes is
common. Basically, the platelets are the mainstay of such
a complicated atheromatous plaque. Thus, much effort
has been directed towards the blockade of these
interestingly activating blood cells. However, all agents
employed intentionally can only block one of the
pathways involved in thrombogenesis (1). Ticlopidine, an
antiplatelet agent, mainly antagonizes ADP-induced
platelet aggregation. On the other hand, it is believed to
be indirectly blocking the final pathway of fibrinogenesis
via glycoprotein IIb/IIIa receptors on platelets (2). The
antiaggregant effects of ticlopidine and aspirin in
coronary interventions have been published elsewhere (35). However, it is not clear to what extent it can
contribute in the setting of acute myocardial infarction.
Accordingly, our aim was to disclose the difference
between monotherapy (aspirin) and therapy in which
ticlopidine was used as an adjunct agent to aspirin in
acute myocardial infarction in terms of mortality,
morbidity and need for revascularization over 3- and 6month periods.

The study was conducted in the Selcuk University,
department of cardiology Konya, from January 1998
through June 1998. All the patients were those admitted
to the coronary care unit with the diagnosis of AMI,
determined by ECG, clinical presentation and enzymatic
assay. Patients were randomized to receive aspirin plus
ticlopidine or aspirin alone after related adjustment was
made with clinical status. All patients underwent maximal
treadmill stress testing (Bruce protocol; ST depression ≥
1 mm was considered positive) and echocardiographic
examination both at 3- and 6-month intervals.
Two groups were assigned: the aspirin group (AG)
and ticlopidine group (TG). After the diagnosis was
clarified, 46 patients received standard therapy (aspirin
300 mg, streptokinase 1.5 MU, beta blocker
(metoprolol) 25 to 100 mg/day, heparin 5000 U bolus
followed by 1000 U/h infusion for 5 to 7 days,
nitroglycerin 10-20 µ/min infusion for 12 to 24 h and
ramipril 1.25 to 2.5 mg in 24 h and thereafter for 6
months. Meanwhile, TG received plus ticlopidine 250 mg
twice daily in 24 h and thereafter for 6 months.
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Patients with Killip’s class 3-4, those who presented
with mechanical complications, post MI angina in 5 days
(due to the onset of ticlopidine effect in 2 to 5 days),
with compromised hepatic and renal functions were
excluded. Patients with signs of pump failure despite
ramipril and thiazid diuretics were given dobutamin
and/or digoxin. Those with ongoing chest pain and
unstable clinical picture due to pump failure or
arrhythymias underwent coronary angiography and
intervention when appropriate.
A comprehensive biochemical assessment was
obtained for each patient focusing on lipid profile within
48 h. All patients underwent echocardiographic
examination and treadmill stress test before discharge to
stratify the current risk for future events. Holter
monitoring,
radionuclid
studies
and
even
electrophysiologic studies were done when indicated.
Patients with low risk were given various doses of
aspirin, metoprolol, ramipril, atorvastatin and isosorbide
mononitrate for follow-up. Exceptionally, TG patients
were called back on day 15 for complete blood count to
determine the major side effect, neutropenia. Patients
were followed up for a mean duration of 6 months; all
attended at 3 and 6 months.
Primary end-points of the study were; recurrent
angina, cardiovascular mortality, reinfarction, heart
failure and stroke in 6 months. Secondary end-points
were coronary angiography and revascularization. During
follow-up, all clinical comprehensive laboratory
assessments were repeated for each case. Results were
analyzed at 3 and 6 months.
Statistics
All statistical calculations were done on SPSS for
Windows 8.0. Categoric variables were expressed as
counts and percentages. Comparisons of categoric
variables were made by Pearson Chi-square test or
Fisher's Exact Chi-square test. In identifying statistical
significance, Student’s t test was used for continuous
variables. The Mann-Whitney U test was used for
continuous variables with marked standard deviation. A p
value of < 0.05 was considered significant. All variables
were given as mean ± standard deviation and percentage.

Results
Ninety patients, 82 male, 8 female, mean age 54 ± 10
years in the ticlopidine group, 55 ± 9 years in the aspirin
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group, were enrolled. Neither group was statistically
different in terms of age, gender, risk factors, infarct
localization or overall therapy. Left ventricular ejection
fractions as a marker of the pump function were almost
identical at both echo and left ventriculography between
groups (Table 1). When the enzymatic assay for the
infarct area was examined no difference between the
groups was observed (p > 0.05).
The extent of coronary artery disease was similar in
the two groups, as well as the degree of stenosis of
epicardial arteries (Table 2). The major side effect of
ticlopidine was neutropenia, as expected, seen in 2
(4.5%) patients. However, there was no statistical
difference between the groups with respect to the side
effect profile. All other tests, concerning hepatic and renal
function, were performed for each patient, and no
significance was found (p > 0.05) (Table 3).
Neither the primary nor secondary end-points showed
any significance, either at 3 months or 6 months,
although the reinfarction rate and need for coronary
bypass surgery were lower in TG (Table 4; Table 5;
15.9% vs. 30.4% at 3 months, 20.5% vs. 30.4% at 6
months for CABG, 4.5% vs. 10.9% at 3 months, 6.8%
vs. 13% at 6 months for reinfarction). Additionally,
echocardiographic examination and treadmill stress
testing either at 3- or 6-month intervals revealed no
difference between the groups with regard to left
ventricular systolic functions or recurrent ischemia (p >
0.05) (Table 4).

Discussion
There are many studies evaluating the role of
antithrombotic agents in acute coronary syndromes, most
of which are published elsewhere (6-8), and built the
basis for their routine use in each individual case. The
efficacy of aspirin as a single antiaggregant agent seems
to be between 35% and 40% at the most, as determined
by sophisticated aggregometers (10,11). This naturally
raises the issue of a more potent antiplatelet regimen
without side effects, which is supposed to bring about
more salutary results for the clinician and the patient. The
particular question should be whether a successful
combination of aspirin and ticlopidine, as in the case of
stenting, would act the same way with AMI. In our study,
the answer was no, although the reinfarction rate and
need for CABG were lower in TG. It is the authors’
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Ticlopidine
(n = 44)
Age
Gender

Female
Male

Aspirin
(n = 46)

p value

54 ±10

55 ±9

0.330

3 (7%)

5 (11%)

0.714

41 (93%)

41 (89%)

0.500

BMI (kg/m2)

26 ± 2.8

25 ± 2.6

0.250

Smoking

30 (68%)

29 (63%)

0.608

Diabetes Mellitus

10 (23%)

6 (13%)

0.230

Hypertension

15 (34%)

10 (22%)

0.191

Heredity (<45 years)

9 (21%)

6 (13%)

0.346

Hyperlipidemia

21 (48%)

24 (52%)

0.673

Low HDL

12 (27%)

14 (30%)

0.741

Previous MI

9 (26%)

9 (20%)

0.916

Anterior

22 (50%)

26 (57%)

0.535

Inferior

16 (36%)

13 (28%)

0.411

Non-Q wave

6 (14%)

7 (15%)

0.831

3 (7%)

4 (9%)

1.000

Table 1.

Patient Characteristics.

Table 2.

Extent of Coronary Artery Disease
and Percent Stenosis of Involved
Coronary Arteries.

‹nfarct localization

Postmenopausal women
Therapy
Thrombolytic Therapy

30 (68%)

28 (61%)

0.469

Aspirin

44 (100%)

46 (100%)

-

Heparin

44 (100%)

46 (100%)

-

Beta blockers

15 (34%)

20 (44%)

0.361
0.940

ACE inhibitors

21 (48%)

30 (65%)

Nitrates

44 (100%)

46 (100%)

-

Ca antagonists

21 (48%)

30 (65%)

0.248

Antiarrhythmics (lidocaine)

4 (9%)

3 (7%)

0.649

Digitalis

9 (21%)

10 (22%)

0.881

Total Cholesterol(mg/dl)

194 ± 44

203 ± 44

0.391

LDL Cholesterol(mg/dl)

121 ± 40

127 ± 36

0.515

HDL Cholesterol(mg/dl)

40 ± 9

40 ± 9

0.954

162 ± 74

180 ± 95

0.537

51 ± 9

50 ± 9

0.50

ESD* (cm)

3.3 ± 0.43

3.3 ± 0.42

0.58

EDD* (cm)

4.9 ± 0.38

4.87 ± 0.44

0.21

Ticlopidine
(n = 44)

Aspirin
(n = 46)

p value

Single Vessel Disease

12 (46.2%)

6 (33.3%)

0.692

Multi Vessel Disease

13 (50%)

11 (61.1%)

0.467

Non-Significant Stenosis

1 (3.8%)

1 (5.6%)

1.000

LAD (% ± ) 17 (67 ± 33)

12 (68 ± 32)

0.810

CX (% ± )

8 (47 ± 38)

0.337

10 (55 ± 37)

0.447

Laboratory

Triglycerides (mg/dl)
EF (%)

*ESD: End Systolic Diameter, *EDD: End Diastolic Diameter

9 (35 ± 39)

RCA (% ± ) 12 (47 ± 37)
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Leucocyte count (cell/mm3)
Blood Urea (mg/dl)
Blood Creatinin (mg/dl)
SGOT (mg/dl)
SGPT (mg/dl)
Total cholesterol (mg/dl)
LDL (mg/dl)
HDL (mg/dl)
Triglycerides (mg/dl)

Treadmill stress testing (positive)
3rd month
6th month
EF (%)
3rd month
6th month
Recurrent Angina
3rd month
6th month
Reinfarction
3rd month
6th month
Mortality
3rd month
6th month
CHF
3rd month
6th month
Stroke

6th month

3rd month

Revascularization
3rd month
6th month
Revascularization Type
None
PTCA-Stent
CABG
None
PTCA-Stent
Re-PTCA-Stent
CABG
Emergency CABG
after PTCA or Stent
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Ticlopidine
(n = 44)

Aspirin
(n = 46)

p value

6732 ± 1274
34 ± 10
1.03 ± 0.2
30 ± 9
25 ± 8
213 ± 39
133 ± 34
39 ± 8
205 ± 854

6881 ± 1219
33 ± 7
0.99 ± 0.2
29 ± 7
24 ± 9
215 ± 32
139 ± 28
40 ± 7
185 ± 63

0.57
0.16
0.30
0.74
0.49
0.75
0.42
0.64
0.22

Ticlopidine
(n = 44)

Aspirin
(n = 46)

p value

10 (22.7%)
8 (18.2%)

11 (23.9%)
13 (28.3%)

0.894
0.258

57.42 ± 12.9
55.48 ± 18.3

54.29 ± 14.8
55.62 ± 14.5

0.296
0.865

22 (50%)
25 (56.8%)

20 (43.5%)
25 (54.3%)

0.535
0.814

2 (4.5%)
3 (6.8%)

5 (10.9%)
6 (13.0%)

0.263
0.325

0
1 (2.3%)

1 (2.2%)
3 (6.5%)

0.325
0.328

7 (15.9%)
7 (15.9%)
0

5 (10.9%)
5 (10.9%)
0

0.482
0.482

Ticlopidine
(n = 44)

Aspirin
(n = 46)

p value

20 (45.5%)
22 (50.0%)

21 (45.7%)
22 (47.8%)

0.985
0.837

24 (54.5%)
13 (29.5%)
7 (15.9%)
22 (50%)
12 (27.3%)
1 (2.3%)
9 (20.5%)
0

25 (54.3%)
7 (15.2%)
14 (30.4%)
24 (52.2%)
7 (15.2%)
0
14 (30.4%)
1 (2.2%)

0.985
0.102
0.103
0.837
0.161
0.489
0.278
1.000

Table 3.

Biochemical Assay at 6 months.

Table 4.

Primary End-Points at 6 months.

Table 5.

Secondary
months.

End-Points

at

6
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opinion that if a larger group of patients were involved,
the difference could be significant.
Contrasting experimental and clinical data on the
additional effects of ticlopidine are present in the
literature (12-15). On the other hand, there are few
studies on combined antiplatelet therapy in the setting of
AMI testing the effects of blocking additive antiaggregant
pathways other than cyclo-oxygenase inhibition (16,17).
The largest trial comparing either aspirin alone vs. aspirin
and ticlopidine or ticlopidine alone vs. aspirin and
dipyridamol combination comes from Ishikawa et al. (16)
with a secondary prevention group trial. All patients in
this study received the antiplatelet agents right at the
beginning, through a mean duration of 12 ± 1.8 months.
The highlighted result was a reduction in MACE (major
cardiac events) in the combination arm of the study with
aspirin and ticlopidin. (3.1% vs. 7.3%, 40% risk
reduction in one year). Another study, conducted by
Balsano et al. (17) (STAI), tried to demonstrate the effect
of ticlopidine in unstable angina. In this study, ticlopidine
showed a 46.8% reduction in MACE compared to aspirin
with a 41% reduction. However, it is not clear in this
randomized but non-blind study if ticlopidine is superior
to aspirin nor was the combination therapy applied during
therapy. Farrell et al. (18) carried out an experimental
study on 9 otherwise healthy volunteers and 325 mg
aspirin was compared with 325 mg aspirin and 250 mg
ticlopidine twice daily. On day 5, aggregometric results
showed no beneficial additive effect over aspirin alone.
Although the figure is tiny, it can give an idea of the
negative basis for the combination therapy.

In TIMI-12 (19), it has been shown that the platelet
reactivity persists after AMI, until the end of the first
month at least. For our part, the possible salutary effect
of adjunctive ticlopidine in the long term can be deduced,
although this remains to be determined by cumulative
data. Similar results have been obtained for aspirin in the
Antiplatelet Trialists Colloboration (20) in 1 and 2 year
periods, showing the established role of antiplatelet
agents in secondary prevention. This is one of the initial
studies trying to compare aspirin vs. aspirin and
ticlopidine in the setting of AMI, adjusted for age, gender,
and medication, AMI localization and secondary
prevention.
The major pitfall of our study was the small number
of patients involved (90) and the lack of a ticlopidine arm
alone during follow-up. However, the effects of
ticlopidine as a single antiplatelet in AMI were taken for
granted, appearing as a proven surrogate for aspirin.
Larger trials are essential in this respect to determine the
net effects of the aspirin + ticlopidin combination.
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